Photodynamic Therapy Agents: ALA and MAL

Overview / Definition Photodynamic therapy (PDT) is a therapeutic procedure that employs a photosensitizing agent and light exposure to induce cytotoxic effects in targeted tissues. The two primary agents used in dermatology are 5-aminolevulinic acid (ALA) and methyl aminolevulinate (MAL). These agents are particularly effective in treating conditions such as actinic keratosis, superficial basal cell carcinoma, and acne. Epidemiology Actinic keratosis is one of the most common precursors to skin cancer, with an estimated prevalence of 10-25% in older adults, especially in fair-skinned populations. The incidence of basal cell carcinoma (BCC), which can also be treated with PDT, is increasing, with over 4 million cases diagnosed annually in the United States alone. Pathophysiology / Mechanism PDT involves three key components: a photosensitizing agent, oxygen, and light. ALA and MAL are precursors in the heme biosynthetic pathway, leading to the accumulation of protoporphyrin IX (PpIX) in the target cells. Upon exposure to specific wavelengths of light (typically 400-700 nm), PpIX is activated, producing reactive oxygen species (ROS) that induce cellular apoptosis and necrosis. ALA: A prodrug that is converted to PpIX within the cells. MAL: Has a higher affinity for neoplastic cells, reducing pain and improving cosmetic outcomes. Clinical Presentation Conditions treated with PDT often present with: Actinic keratosis: Rough, scaly lesions on sun-exposed skin. Superficial basal cell carcinoma: Pearly papules or plaques, often with a translucent quality. Acne: Inflammatory lesions and comedones, particularly in moderate to severe cases. Diagnosis / Workup The diagnosis of conditions suitable for PDT is primarily clinical, supported by patient history and examination. A biopsy may be warranted in atypical presentations to confirm diagnosis, particularly in suspected basal cell carcinoma or squamous cell carcinoma. Treatment / Management The typical management protocol for